November 28, 2018
ObsEva kicks off third phase of testing its nolasiban for backing up pregnancy rates and live births for in-vitro fertilization
ObsEva SA has started testing in third phase its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology (ART), or in-vitro fertilization (IVF).